NUCYNTA (tapentadol hydrochloride) by Humanwell Pharmaceutical is centrally-acting synthetic analgesic. First approved in 2012.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
NUCYNTA is an oral synthetic analgesic combining mu-opioid receptor agonism with norepinephrine reuptake inhibition for centrally-acting pain relief. The dual mechanism derives analgesia from both opioid and noradrenergic pathways, though the clinical significance of this combination remains incompletely characterized. It is indicated for moderate to severe pain management in adult patients.
Product approaching loss of exclusivity (July 2026) with moderate competitive pressure (35/100), signaling transition from growth team to generic defense and lifecycle management roles.
centrally-acting synthetic analgesic. The exact mechanism of action is unknown. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a mu-opioid receptor (MOR) agonist and a norepinephrine reuptake inhibitor (NRI). Analgesia in animal models is derived from…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain
A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain
Worked on NUCYNTA at Humanwell Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Working on NUCYNTA in 2025 offers limited growth opportunity given imminent LOE and zero current linked job openings, making it a defensive rather than growth career move. Professionals joining should expect focus on generic mitigation, pricing protection, and transition planning rather than market expansion.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo